Credit: DIGITIMES
OpenAI acquires Orchestra Bio to advance AI drug development
并购
英文
OpenAI has acquired biotech startup Orchestra Bio and will integrate its team and technology into its life sciences research platform, Rosalind, expanding AI applications in drug development in an effort to accelerate the arrival of new therapies.
本站仅提供摘要，完整内容请阅读原文（版权归原媒体所有）
https://www.digitimes.com/news/a20261022PD203/openai-biotech-acquisition-medical-startup.html
相关阅读
10-20 15:48
China's S2C–HyperSilicon merger targets hardware emulation gap in domestic EDA with Empyrean backing
10-20 11:57
10-19 13:21